INS and type 1 diabetes mellitus: In a randomized study by Kuhadia et al,27 involving 72 individuals (placebo = 18, liraglutide = 54) with T1D, who were overweight or had obesity, the addition of liraglutide (1.2, 1.8 mg) to insulin over a 12-week period resulted in modest reductions in average blood glucose, HbA1c, small reductions in insulin doses, significant weight loss, decreased postprandial glucose concentration, and frequent gastrointestinal (GI) side effects.